Literature DB >> 24915068

Arterial and venous aneurysms associated with arteriovenous malformations.

Giuseppe D'Aliberti1, Giuseppe Talamonti1, Marco Cenzato1, Alessandro La Camera1, Alberto Debernardi2, Luca Valvassori3, Piano Mariangela3, Michele Nichelatti4.   

Abstract

OBJECTIVE: To identify prioritization based on hemorrhagic risk and indications for treatment of arterial and venous aneurysms associated with arteriovenous malformation (AVM).
METHODS: From a global series of 400 consecutively treated AVMs, 34 patients (8.5%) with 45 arterial or venous aneurysms were extrapolated. These 45 lesions were classified as unrelated aneurysms (n = 5 cases; 11.%), flow-related aneurysms (n = 18 cases; 40%), and intranidal and postnidal venous aneurysms (n = 22; 49.%). The 18 flow-related aneurysms were further divided into remote (n = 6 cases) and adjacent (n = 12 cases) types. Of 45 aneurysms associated with AVMs, 15 were unruptured with a 5-year mean follow-up. Various possible risk indicators were considered and measured by univariate and multivariate analyses.
RESULTS: During the follow-up period, 1 of 15 unruptured aneurysms bled, and the patient died. A significantly different bleeding incidence was found between unrelated aneurysm and flow-related aneurysm types (P = 0.002). Bleeding was significantly less probable in flow-related remote aneurysm type than in venous and flow-related adjacent aneurysm types (P = 0.007). The location of the aneurysm was the only true risk factor for bleeding; the other parameters had no influence on bleeding.
CONCLUSIONS: In this series, different subtypes of aneurysms associated with AVMs had different clinical behaviors. The bleeding risk of the unrelated aneurysm and the flow-related remote aneurysm types should be considered almost the same as any other unruptured aneurysm. In other words, bleeding risk should be considered taking into account the parameters established by the International Study of Unruptured Intracranial Aneurysms (location, size, and morphology). Conversely, flow-related adjacent aneurysm and venous aneurysm types have significantly higher bleeding potentials.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebral aneurysms; Cerebral arteriovenous malformations; Embolization; Hematoma; Surgery

Mesh:

Year:  2014        PMID: 24915068     DOI: 10.1016/j.wneu.2014.05.037

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Targeted endovascular treatment for ruptured brain arteriovenous malformations.

Authors:  Kun Hou; Kan Xu; Xuan Chen; Tiefeng Ji; Yunbao Guo; Jinlu Yu
Journal:  Neurosurg Rev       Date:  2019-11-13       Impact factor: 3.042

Review 2.  Aneurysms Associated with Brain Arteriovenous Malformations.

Authors:  S K Rammos; B Gardenghi; C Bortolotti; H J Cloft; G Lanzino
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-23       Impact factor: 3.825

3.  Cerebral arteriovenous malformations in the era of embolization for angiographic cure: a single-center experience in Egypt.

Authors:  Mohamed K Elewa
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-05-03

Review 4.  Regression of a symptomatic varix after transarterial embolization of a brain arteriovenous malformation: A case report and literature review.

Authors:  Guichen Li; Guangming Wang; Jing Yu; Kun Hou; Jinlu Yu
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Transvenous Coil-plugging Technique for a Symptomatic Giant Varix Associated with Arteriovenous Malformation.

Authors:  Yuji Kushi; Tetsu Satow; Taichi Ikedo; Tsuyoshi Ohta; Takeshi Hara; Jun C Takahashi; Koji Iihara; Hiroharu Kataoka
Journal:  NMC Case Rep J       Date:  2021-08-21

6.  Hybrid operation for arteriovenous malformations with associated multiple intracranial aneurysms and subarachnoid hemorrhage: Case report.

Authors:  Fei Xie; Lin Huang; Yongqiang Ye; Jianqiang Hao; Janwei Lv; Seidu A Richard
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.